Last reviewed · How we verify
NCT04055415
Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension
Phase 1, PHASE2 trial testing adipose derived mesenchymal stem cells in Pulmonary Hypertension in 60 participants. Status unknown.
1 August 2020
Quick facts
| Lead sponsor | Liaocheng People's Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 August 2019 |
| Primary completion | 1 August 2020 |
| Estimated completion | 1 February 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- adipose derived mesenchymal stem cells
- Conventional drug therapy（expectorant，bronchodilator） — full drug profile →
Conditions studied
- Pulmonary Hypertension — all drugs for Pulmonary Hypertension →
Sponsor
Liaocheng People's Hospital
Who can join
Adults 40 to 75, any sex, with Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pulmonary arterial hypertension is a disease characterised by pathological changes in the pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and pulmonary artery pressure. Right ventricular failure is the main cause of death in patients with pulmonary arterial hypertension, and the ability of the right ventricle to adapt to the progressive increase in pulmonary vascular resistance associated with changes to the pulmonary vasculature in pulmonary arterial hypertension is the main determinant of a patient's functional capacity and survival.Mesenchymal stem cells (MSCs)are a subset of adult stem cells residing in many tissues, including bone marrow(BM), adipose tissue, umbilical cord blood. Recent experimental findings have shown the ability of MSCs to home to damaged tissues and to produce paracrine factors with anti-inflammatory properties, potentially resulting in reduction of inflammation and functional recovery of the damaged tissues.It was found that MSCs can significantly improve the pulmonary hemodynamics, lung tissue gross and decrease the pulmonary artery pressure, middle artery thickness and right cardiac hypertrophy by intravenous injection.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Clinical Trials of Mesenchymal Stromal Cells Therapy.
Kouchakian MR, Baghban N, Moniri SF, Baghban M, et al · · 2021 · cited 30× · PMID 34745268 · DOI 10.1155/2021/1634782 -
Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review.
Chen X, Wang F, Huang Z, Wu Y, et al · · 2021 · cited 23× · PMID 34220313 · DOI 10.7150/ijms.59218 -
Emerging therapies for right ventricular dysfunction and failure.
Klinke A, Schubert T, Müller M, Legchenko E, et al · · 2020 · cited 22× · PMID 33224787 · DOI 10.21037/cdt-20-592 -
Stem cell therapy in pulmonary hypertension: current practice and future opportunities.
Zheng R, Xu T, Wang X, Yang L, et al · · 2023 · cited 14× · PMID 37758272 · DOI 10.1183/16000617.0112-2023
Verify or expand the search:
- PubMed search for NCT04055415
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Hypertension
Currently open trials in the same condition.
- NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
- NCT07073820 — A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P · Phase 2 · recruiting
- NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
- NCT07187206 — Safety and Efficacy of FETO in CDH Phase III · Phase 3 · recruiting
- NCT07206173 — Londrina Activities of Daily Living Protocol in Pulmonary Hypertension · recruiting
Other Liaocheng People's Hospital trials
Trials by the same sponsor.
- NCT06302582 — Platelet Rich Plasma Combined With Human Umbilical Cord Mesenchymal Stem Cells for Stage 3 and 4 Stress Injury · Phase 1, PHASE2 · unknown
- NCT05586464 — Eradication of Helicobacter Pylori With Bismuth Agent Quadruple and Traditional Chinese Medicine · Phase 1 · unknown
- NCT06823791 — Furazolidone Quadruple Regimen Eradicate H. Pylori Infection · Phase 1, PHASE2 · completed
- NCT05353634 — Metagenomic Sequencing in Clinical Infectious Diseases · completed
- NCT03166865 — Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04055415 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liaocheng People's Hospital
- Last refreshed: 13 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04055415.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing